Searchable abstracts of presentations at key conferences in endocrinology

ea0049oc12.5 | Pituitary Clinical | ECE2017

Effects of pegvisomant and somatostatin receptor ligands on risk of vertebral fractures in patients with Acromegaly

Chiloiro Sabrina , Mazziotti Gherardo , Giampietro Antonella , Formenti Anna Maria , Bianchi Antonio , Mormando Marilda , Pontecorvi Alfredo , Giustina Andrea , De Marinis Laura

Acromegalic osteopathy is an emerging complication of chronic GH excess characterized by increase in bone turnover, deterioration in bone microarchitecture and high risk of vertebral fractures (VFs). Medical therapies may exert direct effects on peripheral targets leading to improvement of clinical outcomes regardless of biochemical control of acromegaly. In this longitudinal study, we compared the effects pegvisomant (PegV) and somatostatin receptor ligands (SRLs) on VF risk ...

ea0022p112 | Bone/Calcium | ECE2010

Risk of vertebral fractures in osteoporotic women: definition of a clinically relevant scale of risk

Fusco Alessandra , Pola Enrico , Mormando Marilda , Colangelo Debora , Aurelio Nasto Luigi , Bianchi Antonio , Ambrogio Logroscino Carlo , De Marinis Laura

Introduction: Osteoporosis is a disease characterized by a low bone mass and the development of nontraumatic fractures, most commonly in the spine. However, bone mineral density (BMD) alone is not completely satisfactory in vertebral fracture risk assessment.Aim of the study: To identify clinical and laboratoristic factors associated with an increased risk of vertebral fractures in osteoporotic Caucasian women and to define a new clinically relevant scal...

ea0041ep928 | Pituitary - Clinical | ECE2016

Bone metabolism in acromegaly

Giampietro Antonella , Chiloiro Sabrina , Mormando Marilda , Bima Chiara , Bracaccia Maria Elena , Piacentini Serena , Tartaglione Linda , Iacovazzo Donato , Bianchi Antonio , De Marinis Laura

Aim: To evaluate calcium and bone metabolism in a monocentric series of acromegaly patients (pts), treated with pegvisomant (PEG) alone or in association to long acting somatostatine analogs.Patients and methods: All pts with at least 24 consecutive months PEG treatment (alone or in combination with SSA) were enrolled. All pts had been tested at least twice/year for biochemical acromegaly-disease evaluation and annually for calcium metabolism and for bon...

ea0035p937 | Pituitary Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>) | ECE2014

IGF1 response to rhGH in adult GHD: role of GH receptor (GHR) isoforms

Bianchi Antonio , Tartaglione Linda , Giampietro Antonella , Milardi Domenico , Angelini Flavia , Mormando Marilda , Lugli Francesca , Piacentini Serena , Grande Giuseppe , Iacovazzo Donato , Chiloiro Sabrina , Pontecorvi Alfredo , Marinis Laura De

The IGF1 response to recombinant human growth hormone (rhGH) showed some individual variability and the responsible factors for this behavior remain unknown. Some studies have emphasized the possible role of isoforms of the GH receptor (GHR), showing conflicting results.Therefore, we investigated the possible influence of the isoforms of the GHR to the diagnosis of GHD and in determining adult hormone replacement therapy responsiveness.<p class="abst...

ea0032p103 | Bone and Osteoporosis | ECE2013

Efficacy and safety of the anabolic therapies in severe osteoporosis: experience of a team of endocrinologists and spine surgeons

Mormando Marilda , Fusco Alessandra , Pola Enrico , Piacentini Serena , Nasto Luigi Aurelio , Colangelo Debora , Chiloiro Sabrina , Bianchi Antonio , Pontecorvi Alfredo , De Marinis Laura

Anabolic therapies represent a major advance in the management of severe osteoporosis. Parathyroid hormone (PTH) and human recombinant PTH peptide 1–34 (Teriparatide) demonstrated an increase in bone mineral density and a significant reduction in vertebral fractures in patients with osteoporosis when given for 18–24 months. The intermittent administration of PTH or teriparatide stimulates osteoblastic function, improves bone architecture and has an additional analges...

ea0020p550 | Neuroendocrinology, Pituitary and Behaviour | ECE2009

Growth hormone receptor polymorphism and the effects of pegvisomant in acromegaly

Bianchi Antonio , Mazziotti Gherardo , Tilaro Laura , Cimino Vincenzo , Porcelli Teresa , Mormando Marilda , Tartaglione Linda , Pontecorvi Alfredo , Giustina Andrea , De Marinis Laura

Clinical trials have demonstrated that pegvisomant therapy is highly efficacious, normalizing serum IGF-I levels in the majority of patients with acromegaly. Multiple factors could influence the dose of pegvisomant required to normalize IGF-I, that ranging from 10 to 40 mg/day. However, the determinants of this variability are unknown and, to date, there is no specific recommendation to adjust the dose to the type of patient. Lack of exon 3 of the Growth Hormone receptor (d3-G...